The pharmacological treatment of opioid addiction—a clinical perspective

This article reviews the main pharmacotherapies that are currently being used to treat opioid addiction. Treatments include detoxification using tapered methadone, buprenorphine, adrenergic agonists such as clonidine and lofexidine, and forms of rapid detoxification. In opioid maintenance treatment (OMT), methadone is most widely used. OMT with buprenorphine, buprenorphine-naloxone combination, or other opioid agonists is also discussed. The use of the opioid antagonists naloxone (for the treatment of intoxication and overdose) and oral and sustained-release formulations of naltrexone (for relapse prevention) is also considered. Although recent advances in the neurobiology of addictions may lead to the development of new pharmacotherapies for the treatment of addictive disorders, a major challenge lies in delivering existing treatments more effectively. Pharmacotherapy of opioid addiction alone is usually insufficient, and a complete treatment should also include effective psychosocial support or other interventions. Combining pharmacotherapies with psychosocial support strategies that are tailored to meet the patients’ needs represents the best way to treat opioid addiction effectively.

[1]  Jeff Ward,et al.  Role of maintenance treatment in opioid dependence , 1999, The Lancet.

[2]  G. Gessa,et al.  Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. , 2000, Drug and alcohol dependence.

[3]  R. Willette.  The development of sustained action preparations of narcotic antagonists. , 1978, NIDA research monograph.

[4]  T. Clausen,et al.  Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. , 2008, Drug and alcohol dependence.

[5]  R. E. Johnson,et al.  Treatment of opioid-dependent pregnant women with buprenorphine. , 2000, Addiction.

[6]  M. Stitzer,et al.  ONE-, THREE-, AND SIX-MONTH OUTCOMES AFTER BRIEF INPATIENT OPIOID DETOXIFICATION , 2001, The American journal of drug and alcohol abuse.

[7]  B. Lester,et al.  Buprenorphine treatment of pregnant opioid--dependent women: maternal and neonatal outcomes. , 2001, Drug and alcohol dependence.

[8]  L. Amato,et al.  Oral naltrexone maintenance treatment for opioid dependence. , 2011, The Cochrane database of systematic reviews.

[9]  Kevin G Lynch,et al.  Prescription OxyContin abuse among patients entering addiction treatment. , 2007, The American journal of psychiatry.

[10]  A. Risbo,et al.  Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia , 1988, Acta anaesthesiologica Scandinavica.

[11]  H. Aschauer,et al.  Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. , 2006, Addiction.

[12]  J. Strang,et al.  Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. , 1990, Addictive behaviors.

[13]  S. Kayemba-kay's,et al.  Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. , 2003, Addiction.

[14]  H. Kleber,et al.  Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. , 2005, JAMA.

[15]  R. Stohler,et al.  Double-blind randomized trial of buprenorphine and methadone in opiate dependence. , 2001, Drug and alcohol dependence.

[16]  R. Mattick,et al.  Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. , 2003, The Cochrane database of systematic reviews.

[17]  I. Abraha,et al.  Sustained‐Release Naltrexone for Opioid Dependence , 2012 .

[18]  P. Magnus,et al.  A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. , 2002, Addiction.

[19]  T. Clausen,et al.  Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. , 2009, Addiction.

[20]  W. Ling,et al.  A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. , 1996, Archives of general psychiatry.

[21]  S. Kandall,et al.  The methadone-maintained pregnancy. , 1999, Clinics in perinatology.

[22]  R. Ali,et al.  Buprenorphine for the management of opioid withdrawal. , 2006, The Cochrane database of systematic reviews.

[23]  E. Nestler,et al.  Molecular basis of long-term plasticity underlying addiction , 2001, Nature Reviews Neuroscience.

[24]  Jason M. White,et al.  Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. , 2003, Addiction.

[25]  P. Griffiths,et al.  Monitoring trends in illicit drug use in Europe: an overview of the work of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) , 2008 .

[26]  M. Ferri,et al.  Heroin maintenance for chronic heroin dependents. , 2005, The Cochrane database of systematic reviews.

[27]  M. Farrell,et al.  Alpha2 adrenergic agonists for the management of opioid withdrawal. , 2004, The Cochrane database of systematic reviews.

[28]  E. Cone,et al.  Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. , 1996, Journal of analytical toxicology.

[29]  A. Paraponaris,et al.  French General Practitioners' Attitudes and Prescription Patterns Toward Buprenorphine Maintenance Treatment , 2005, Journal of addictive diseases.

[30]  E. Ravndal,et al.  Opioid Maintenance Treatment during Pregnancy: Occurrence and Severity of Neonatal Abstinence Syndrome , 2009, European Addiction Research.

[31]  M. Brekke,et al.  Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study , 2008, BMC public health.

[32]  J. Jaffe,et al.  A controlled trial of buprenorphine treatment for opioid dependence. , 1992, JAMA.

[33]  D. Ladewig.  [Naltrexone--an effective aid in the psychosocial rehabilitation process of former opiate dependent patients]. , 1990, Therapeutische Umschau. Revue therapeutique.

[34]  J. Bell,et al.  A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. , 2004, Drug and alcohol review.

[35]  Willette Re.  The development of sustained action preparations of narcotic antagonists. , 1976 .

[36]  M. Stitzer,et al.  A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. , 1995, Drug and alcohol dependence.

[37]  R. Jagsch,et al.  Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. , 2005, Addiction.

[38]  A. Ritter,et al.  LAAM maintenance vs methadone maintenance for heroin dependence. , 2002, The Cochrane database of systematic reviews.

[39]  Laura Amato,et al.  An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. , 2005, Journal of substance abuse treatment.

[40]  A. Rosenblum,et al.  Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. , 2001, The Mount Sinai journal of medicine, New York.

[41]  D. Julius.  NIDA's naltrexone research program. , 1976, NIDA research monograph.

[42]  A. Uchtenhagen.  Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence , 2009 .

[43]  J. Marsden,et al.  The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. , 2003, Addiction.

[44]  J. Ahmadi.  Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. , 2003, Journal of substance abuse treatment.

[45]  M. Ferri,et al.  Heroin maintenance for chronic heroin dependents. , 2003, The Cochrane database of systematic reviews.

[46]  L. San,et al.  Methadone and quality of life , 1999, The Lancet.

[47]  L. Amato,et al.  Methadone at tapered doses for the management of opioid withdrawal. , 2003, The Cochrane database of systematic reviews.

[48]  Y. Bao,et al.  A Meta-Analysis of Retention in Methadone Maintenance by Dose and Dosing Strategy , 2009, The American journal of drug and alcohol abuse.

[49]  Caitriona Cody,et al.  Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge. , 2006, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[50]  M. Kreek,et al.  Methadone‐Related Opioid Agonist Pharmacotherapy for Heroin Addiction: History, Recent Molecular and Neurochemical Research and Future in Mainstream Medicine , 2000, Annals of the New York Academy of Sciences.

[51]  F. Faggiano,et al.  Methadone maintenance at different dosages for opioid dependence. , 2003, The Cochrane database of systematic reviews.

[52]  L. Marsch.  The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. , 1998, Addiction.

[53]  M. Gossop,et al.  Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial , 2009, British Journal of Psychiatry.

[54]  P. Stolley,et al.  Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. , 1993, Journal of acquired immune deficiency syndromes.

[55]  M. Malaguarnera,et al.  Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers , 2005, Psychopharmacology.

[56]  J. Ahmadi,et al.  Twelve-month maintenance treatment of opium-dependent patients. , 2004, Journal of substance abuse treatment.

[57]  Jason M. White,et al.  Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. , 2004, Addiction.

[58]  R. Hartnoll,et al.  Evaluation of heroin maintenance in controlled trial. , 1980, Archives of general psychiatry.

[59]  M. Heilig,et al.  1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial , 2003, The Lancet.

[60]  Buprenorphine , 2016, Reactions Weekly.

[61]  G. Perugi,et al.  QTc Interval Prolongation in Patients on Long-Term Methadone Maintenance Therapy , 2004, European Addiction Research.

[62]  K. Berridge,et al.  The psychology and neurobiology of addiction: an incentive-sensitization view. , 2000, Addiction.

[63]  J. Strang,et al.  Opiate Withdrawal Symptoms in Response to 10-Day and 21-Day Methadone Withdrawal Programmes , 1989, British Journal of Psychiatry.

[64]  R P Mattick,et al.  Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. , 2008, The Cochrane database of systematic reviews.

[65]  J. Henningfield,et al.  Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction , 1989, Clinical pharmacology and therapeutics.

[66]  Factors Associated with Relapse Among Opiate Addicts in an Out-patient Detoxification Programme , 1992, British Journal of Psychiatry.

[67]  G. Woody,et al.  Naltrexone for heroin dependence treatment in St. Petersburg, Russia. , 2004, Journal of substance abuse treatment.

[68]  J. Strang,et al.  Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study , 2003, BMJ : British Medical Journal.

[69]  C. O'brien,et al.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. , 2006, Archives of general psychiatry.

[70]  J. Micallef,et al.  Buprenorphine prescription by general practitioners in a French region. , 2002, Drug and alcohol dependence.

[71]  D. Shah,et al.  Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. , 2006, Archives of internal medicine.

[72]  R. Hubbard,et al.  Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). , 2003, Journal of substance abuse treatment.

[73]  W. van den Brink,et al.  An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. , 2002, Addiction.

[74]  W. Ling,et al.  Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. , 1998, Addiction.

[75]  D. Ladewig,et al.  Comparison of Buprenorphine and Methadone in the Treatment of Opioid Dependence , 1998, European Addiction Research.

[76]  J. Strang,et al.  Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. , 2000, Drug and alcohol dependence.

[77]  R. Schottenfeld,et al.  Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial , 2008, The Lancet.

[78]  E. Witztum,et al.  The efficacy of naltrexone in preventing reabuse of heroin after detoxification , 1994, Biological Psychiatry.

[79]  J. Caplehorn,et al.  Retention in methadone maintenance and heroin addicts' risk of death. , 1994, Addiction.

[80]  J. Mørland,et al.  Codeine and clinical impairment in samples in which morphine is not detected , 2003, European Journal of Clinical Pharmacology.

[81]  J. Strang,et al.  Rapid opiate detoxification treatments , 1999 .

[82]  M. Krausz,et al.  Heroin-assisted treatment for opioid dependence: randomised controlled trial. , 2007, The British journal of psychiatry : the journal of mental science.

[83]  E. Cone,et al.  Elevated drug saliva levels suggest a "depot-like" effect in subjects treated with sublingual buprenorphine. , 1990, NIDA research monograph.

[84]  P. X. Iten,et al.  Medical prescription of heroin to chronic heroin addicts in Switzerland - a review. , 2001, Forensic science international.

[85]  K. Preston,et al.  Acute administration of buprenorphine in humans: partial agonist and blockade effects. , 1995, The Journal of pharmacology and experimental therapeutics.

[86]  J. Camí,et al.  Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. , 1991, British journal of addiction.

[87]  D. Ziedonis,et al.  Buprenorphine versus Methadone Maintenance for Opioid Dependence , 1993, The Journal of nervous and mental disease.

[88]  M. Stitzer,et al.  Comparison of buprenorphine and methadone in the treatment of opioid dependence. , 1994, The American journal of psychiatry.

[89]  B. Berkowitz.  The Relationship of Pharmacokinetics to Pharmacological Activity: Morphine, Methadone and Naloxone , 1976, Clinical pharmacokinetics.

[90]  S. Kasper,et al.  Buprenorphine versus methadone maintenance for the treatment of opioid dependence. , 1999 .

[91]  T. Kosten,et al.  Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. , 2005, The American journal of psychiatry.

[92]  J. Tignol,et al.  French field experience with buprenorphine. , 2004, The American journal on addictions.

[93]  J. P. Gonzalez,et al.  Naltrexone , 1988, Drugs.

[94]  Rua da Cruz.  The EMCDDA annual report 2010: the state of the drugs problem in Europe. , 2010, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[95]  J. Strang,et al.  Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. , 1998, Drug and alcohol dependence.

[96]  B. Lester,et al.  Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. , 2005, Drug and alcohol dependence.

[97]  A. Kastelic,et al.  Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. , 2008, Addiction.

[98]  J. Bramness,et al.  Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. , 2007, Drug and alcohol dependence.

[99]  G. Woody,et al.  Naltrexone pharmacotherapy for opioid dependent federal probationers. , 1997, Journal of substance abuse treatment.

[100]  J. Bouchez,et al.  Substitution with Buprenorphine in Methadone- and Morphine Sulfate-Dependent Patients , 1998, European Addiction Research.

[101]  M. Auriacombe,et al.  Why buprenorphine is so successful in treating opiate addiction in France , 2007, Current psychiatry reports.

[102]  M. Gossop,et al.  Comparison of Buprenorphine and Methadone in the Treatment of Opiate Withdrawal: Possible Advantages of Buprenorphine for the Treatment of Opiate-Benzodiazepine Codependent Patients? , 2007, Journal of clinical psychopharmacology.

[103]  J. Marsden,et al.  Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. , 2001, Drug and alcohol dependence.

[104]  W. Hall,et al.  A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. , 2003, Drug and alcohol dependence.

[105]  J. Strang,et al.  Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. , 1999, The American journal on addictions.

[106]  M. Gossop.  Clonidine and the treatment of the opiate withdrawal syndrome. , 1988, Drug and alcohol dependence.

[107]  G. Stimson,et al.  Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. , 2002, Addiction.

[108]  G. Hulse,et al.  Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. , 2009, Archives of general psychiatry.

[109]  M. Gold,et al.  Naltrexone in addicted business executives and physicians. , 1984, The Journal of clinical psychiatry.